DrugPatentWatch Database Preview
Email this page to a colleague
« Back to Dashboard
Sumavel Dosepro is a drug marketed by Endo Ventures Ltd and is included in one NDA. There are nine patents protecting this drug.
This drug has thirty-two patent family members in nine countries.
The generic ingredient in SUMAVEL DOSEPRO is sumatriptan succinate. There are twenty-four drug master file entries for this compound. Thirty-two suppliers are listed for this compound. Additional details are available on the sumatriptan succinate profile page.
A generic version of SUMAVEL DOSEPRO was approved as sumatriptan succinate by WEST-WARD PHARMS INT on February 6th, 2009.
Summary for SUMAVEL DOSEPRO
|Raw Ingredient (Bulk) Api Vendors:||103|
|Formulation / Manufacturing:||see details|
|Drug Prices:||Drug price information for SUMAVEL DOSEPRO|
|What excipients (inactive ingredients) are in SUMAVEL DOSEPRO?||SUMAVEL DOSEPRO excipients list|
|DailyMed Link:||SUMAVEL DOSEPRO at DailyMed|
Recent Clinical Trials for SUMAVEL DOSEPRO
Identify potential brand extensions & 505(b)(2) entrants
|Synteract, Inc.||Phase 4|
|Zogenix, Inc.||Phase 4|
|Country||Patent Number||Estimated Expiration|
|South Africa||9601907||⤷ Free Forever Trial|
|United Kingdom||0127942||⤷ Free Forever Trial|
|China||1220613||⤷ Free Forever Trial|
|Slovakia||139398||⤷ Free Forever Trial|
|Japan||2005506153||⤷ Free Forever Trial|
|Brazil||9612003||⤷ Free Forever Trial|
|Austria||231402||⤷ Free Forever Trial|
|>Country||>Patent Number||>Estimated Expiration|